A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies

NCT03130959 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Various Advanced Cancer

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb